Abstract Number: 1245 • ACR Convergence 2021
Characteristics of RA Patients Treated with JAK Inhibitors Before versus After VTE Warnings: Results of a Real-World Multicentric Study
Background/Purpose: In recent decades, the therapeutic arsenal in RA has dramatically expanded. Baricitinib (BARI) and Tofacitinib (TOFA) were the first JAK inhibitors (JAKi) to be…Abstract Number: 1442 • ACR Convergence 2021
Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
Background/Purpose: With the arrival of new Janus kinase inhibitors (JAKi), with different JAK inhibition profiles, there is the possibility of using a second JAKi in…Abstract Number: 1596 • ACR Convergence 2021
Changes in Patient-Reported Outcome (PRO) Scores During the COVID-19 Pandemic: Data from the ArthritisPower Research Registry
Background/Purpose: The COVID-19 pandemic caused particular concern among patients with autoimmune and rheumatic disease (ARD) due to increased risk of infection, and heightened sense of…Abstract Number: 1660 • ACR Convergence 2021
Relationship Between Risk of New Onset Diabetes Mellitus and Exposure to Individual Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects glucose metabolism, mainly insulin resistance, which can lead to diabetes mellitus (DM). Although there…Abstract Number: 1676 • ACR Convergence 2021
Safety of Baricitinib in Japanese Patients with Rheumatoid Arthritis (RA): The 2020 Interim Report from All-case Post Marketing Surveillance in Clinical Practice
Background/Purpose: An all-case post marketing surveillance (PMS) of baricitinib, that started in Sep 2017, collects safety and effectiveness for the first 24 weeks of treatment…Abstract Number: 1692 • ACR Convergence 2021
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: 3-year Results from the SELECT-EARLY Study
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, demonstrated significant improvements in signs, symptoms, and structural inhibition as monotherapy (mono) vs methotrexate (MTX) in MTX-naïve…Abstract Number: 1709 • ACR Convergence 2021
Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial
Background/Purpose: Mesenchymal stem cell (MSC) therapy represents a promise for the treatment of autoimmune diseases due to its potent immunomodulatory effect. We investigated the long-term…Abstract Number: 1924 • ACR Convergence 2021
Patient Clustering Based on Multimorbidity Patterns Predicts Healthcare Utilization and Mortality in Rheumatoid Arthritis Within Independent Real-World Datasets
Background/Purpose: Rheumatoid arthritis (RA) leads to substantial healthcare utilization and premature mortality. Prior work has demonstrated that the overlapping presence of comorbid chronic conditions, termed…Abstract Number: 0023 • ACR Convergence 2021
Investigating Temporal Changes in Pregnancy Among Women with Rheumatoid Arthritis and Healthy Women Using Co-expression Network Analysis
Background/Purpose: Rheumatoid arthritis (RA), while still an incurable disease, can often improve naturally during pregnancy. The specific mechanism(s) underlying this pregnancy-induced improvement, however, are not…Abstract Number: 0039 • ACR Convergence 2021
Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?
Background/Purpose: Mucosal surfaces may be involved in the pathophysiology of rheumatoid arthritis (RA) (1). IgA is the most abundant class of immunoglobulin at mucosal sites…Abstract Number: 0135 • ACR Convergence 2021
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and…Abstract Number: 0200 • ACR Convergence 2021
In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes
Background/Purpose: International guidelines stress timely DMARD-initiation in early arthritis, also when classification-criteria are not yet fulfilled. Consequently, undifferentiated arthritis (UA)-patients are increasingly treated despite placebo-controlled…Abstract Number: 0278 • ACR Convergence 2021
Higher Prevalence of Eccentric Hypertrophy in Rheumatoid Arthritis Patients: A Case-Control Study
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have a higher prevalence of cardiovascular diseases and a strong association with abnormalities in the left ventricular (LV) geometry.…Abstract Number: 0306 • ACR Convergence 2021
Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
Background/Purpose: Allergic disorders are occasionally seen in patients with primary Sjögren's syndrome (pSS) [1]. Risk factors are unclear for allergic disorders.We aimed to compare the…Abstract Number: 0515 • ACR Convergence 2021
The Extracellular Sulfatase-2 Inhibitor OKN-007 Abrogates TNF-α-induced Inflammatory Mediators in Human Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: Recent unpublished findings from our lab show that the extracellular enzyme sulfatase-2 (Sulf-2) facilitates pro-inflammatory TNF-α signaling which activates rheumatoid arthritis synovial fibroblasts (RASFs).…
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 188
- Next Page »